➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Mallinckrodt
Express Scripts
Baxter
Merck

Last Updated: May 27, 2020

DrugPatentWatch Database Preview

RYZODEG 70/30 Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for RYZODEG 70/30

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Novo Nordisk A/SN/A

See all RYZODEG 70/30 clinical trials

Recent Litigation for RYZODEG 70/30

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SMITH v. NOVO NORDISK INC.2016-08-08

See all RYZODEG 70/30 litigation

Company Disclosures: US Patents for RYZODEG 70/30

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2021-01-05 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DE) 2023-08-05 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for RYZODEG 70/30

These patents were identified by searching patent claims

Supplementary Protection Certificates for RYZODEG 70/30

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1390036-0 Sweden   Start Trial PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
2013/034 Ireland   Start Trial PRODUCT NAME: INSULIN DEGLUDEC; NAT REGISTRATION NO/DATE: EU/1/12/807-001, 004, 005, 007-009, 012, 013 015 20130121
92213 Luxembourg   Start Trial PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001-4-5-7-8-9-12-13-15 TRESIBA 20130123
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
AstraZeneca
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.